In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...
The treatment – one of two new drugs to target a cause of the disease – has been considered by the medicines regulator and ...
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...
A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...
Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate ...
Posterial Cortical Atrophy, sometimes called Benson’s disease, is a rare degenerative brain condition that affects the back ...
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...
New details have emerged about how Alzheimer’s disease affects the brain. Researchers led by the Allen Institute for Brain Science in Seattle and University of Washington Medicine have ...
Alzheimer's disease may damage the brain in two distinct phases, based on new research using sophisticated brain mapping ...
An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...
Rensselaer Polytechnic Institute (RPI) has been awarded two grants by the National Institute on Aging (NIA) to train graduate ...
Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S.
Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback